2016 Fiscal Year Final Research Report
A new therapeutic target of platinum resistance ovarian cancer
| Project/Area Number |
15K20142
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Keywords | 婦人科腫瘍 / プラチナ耐性卵巣癌 / IMP-2 |
|---|
| Outline of Final Research Achievements |
In this study, we investigated the role of IMP-2 in platinum resistance ovarian cancer cells which had high level expression of IMP-2. In platinum resistance ovarian cancer lines, knockdown the expression of IMP-2 improved the sensitivity of cisplatin in vitro. Compared with control platinum resistance ovarian cancer cells (A2780/CisR cells), knockdown of IMP-2 induced roughly 3-fold greater chemosensitization to cisplatin (IC50: 167μM to 54 μM; p<0.01) To elucidate the mechanism underlying platinum resistance induced by IMP-2, intracellular platinum accumulation of A2780/CisR control cells, A2780/CisR silencing IMP-2 cells after cisplatin exposure were analyzed. No significantly chage of platinum had accumulated in A2780/CisR silencing IMP-2 cells compared with control cells (p= 0.24). Thus, intracellular platinum accumulation was not changed in A2780/CisR silencing IMP-2 cells. To perform further investigation, we generate stable IMP-2 over expression in A2780 cell lines.
|
| Free Research Field |
婦人科腫瘍
|
